New drug combo shows promise for MET-Positive lung cancer in phase 3 trial

NCT ID NCT06930794

Recruiting now Disease control Sponsor: Beijing Pearl Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

First seen Dec 08, 2025 · Last updated May 13, 2026 · Updated 18 times

Summary

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with a specific type of advanced lung cancer (MET-positive non-squamous NSCLC) live longer without their cancer growing. About 300 adults who have not had prior treatment for their advanced cancer will be randomly assigned to receive either the drug combo or chemo alone. The goal is to see if the combo improves outcomes and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100021, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER